These results are in line with the pivotal PrefHer study (Pivot et al., 2017a) and underscore the clinical importance of incorporating patient-centered considerations, such as comfort, treatment burden, and convenience, into therapeutic decision-making for HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.